Dr. Wen-Kai Weng, MDPHD is a Hematology / Oncology Specialist - Hematologist (Blood) practicing in Stanford, CA
He has not yet shared a personalized biography with Doctor.com.
| University | Degree | Focus | Graduated |
|---|---|---|---|
| Chungshan Medical College | Medical Degree | 1988 |
| Institution | Focus | Year |
|---|---|---|
| Internship - University Of Texas Medical School | 1997 | |
| Residency - University of Texas Medical School | 1999 | |
| Fellowship - Stanford University School of Medicine,Stanford, Ca, United States | 2002 |
| Certification | Cert. Body | Year |
|---|---|---|
| Internal medicine | Internal Medicine | 2007 |
| Internal medicine Sub-Specialty: Medical Oncology | Internal Medicine | Not Specified |
| Position | Organization | Time |
|---|---|---|
| Assistant Professor of Medicine | Stanford University Medical Center | Present |
| Publication | Publisher | Title | Published |
|---|---|---|---|
| Other Publication | journal of clinical investigation | Targeting CD137 enhances the efficacy of cetuximab. | 2014 |
| Other Publication | Biology of blood and marrow transplantation | Total lymphoid irradiation-antithymocyte globulin conditioning | 2014 |
| Other Publication | SCIENCE TRANSLATIONAL MEDICINE | Minimal residual disease monitoring with high | 2013 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Cancer Vaccines and T Cell Therapy | 2013 |
| Other Publication | BLOOD | Prophylactic rituximab after allogeneic transplantation decreases B | 2012 |
| Other Publication | AMERICAN JOURNAL OF HEMATOLOGY | The histone deacetylase inhibitor, romidepsin | 2012 |
| Other Publication | BONE MARROW TRANSPLANTATION | Tandem chemo-mobilization followed by high | 2012 |
| Other Publication | JOURNAL OF CLINICAL INVESTIGATION | Stimulation of natural killer cells with a CD137 | 2012 |
| Other Publication | BLOOD | Transcriptome sequencing in Sezary syndrome identifies Sezary cell | 2012 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Adoptive Immunotherapy with Cytokine | 2011 |
| Other Publication | BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | Phase I/II Trial of GN-BVC | 2010 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | The IgG Fc Receptor Fc?RIIIa 158 V | 2010 |
| Other Publication | BLOOD | TLI and ATG conditioning with low risk of graft-versus | 2009 |
| Other Publication | LEUKEMIA & LYMPHOMA | Genetic polymorphism of the inhibitory IgG Fc receptor FcRIIb is not | 2009 |
| Other Publication | LEUKEMIA & LYMPHOMA | Immunoglobulin G Fc Receptor Polymorphisms Do Not Correlate with Response to Chemotherapy or | 2009 |
| Other Publication | LEUKEMIA & LYMPHOMA | Tumor-specific recombinant idiotype immunisation after chemotherapy as initial treatment for | 2009 |
| Other Publication | CLINICAL CANCER RESEARCH | A Polymorphism in the Complement Component C1qA Correlates with Prolonged Response Following | 2008 |
| Other Publication | BLOOD | The antileukemia activity of a human anti-CD40 antagonist antibody, HCD122 | 2008 |
| Other Publication | BLOOD | Humoral immune response | 2007 |
| Other Publication | American Society of Clinical Oncology Educational Book | Immune-mediated antitumor effects with antibody therapy. | 2005 |
| Other Publication | JOUNRAL OF CLINICAL ONCOLOGY | Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune | 2004 |
| Other Publication | JOURNAL OF CLINICAL ONCOLOGY | Two immunoglobulin G fragment C receptor polymorphisms independently predict response | 2003 |
| Other Publication | LEUKEMIA & LYMPHOMA | Hepatitis C virus (HCV) and lymphomagenesis | 2003 |
| Other Publication | BLOOD | Expression of complement inhibitors CD46, CD55 | 2001 |
| Other Publication | JOURNAL OF IMMUNOLOGY | Differential induction of DNA-binding activities following CD19 cross | 1997 |
| Other Publication | JOURNAL OF BIOLOGICAL CHEMISTRY | SIGNALING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN | 1994 |
| Other Publication | JOURNAL OF IMMUNOLOGY | FUNCTIONAL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS | 1993 |
| Other Publication | jourl of clinical investigation | Targeting CD137 enhances the efficacy of cetuximab. | 2014 |
| Other Publication | SCIENCE TRANSLATIOL MEDICINE | Minimal residual disease monitoring with high | 2013 |
| Other Publication | AMERICAN JOURL OF HEMATOLOGY | The histone deacetylase inhibitor, romidepsin | 2012 |
| Other Publication | JOURL OF CLINICAL INVESTIGATION | Stimulation of tural killer cells with a CD137 | 2012 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | The IgG Fc Receptor Fc?RIIIa 158 V | 2010 |
| Other Publication | LEUKEMIA & LYMPHOMA | Tumor-specific recombint idiotype immunisation after chemotherapy as initial treatment for | 2009 |
| Other Publication | American Society of Clinical Oncology Educatiol Book | Immune-mediated antitumor effects with antibody therapy. | 2005 |
| Other Publication | JOUNRAL OF CLINICAL ONCOLOGY | Clinical outcome of lymphoma patients after idiotype vaccition is correlated with humoral immune | 2004 |
| Other Publication | JOURL OF CLINICAL ONCOLOGY | Two immunoglobulin G fragment C receptor polymorphisms independently predict response | 2003 |
| Other Publication | JOURL OF IMMUNOLOGY | Differential induction of D-binding activities following CD19 cross | 1997 |
| Other Publication | JOURL OF BIOLOGICAL CHEMISTRY | SIGLING THROUGH CD19 ACTIVATES VAV MITOGEN-ACTIVATED PROTEIN | 1994 |
| Other Publication | JOURL OF IMMUNOLOGY | FUNCTIOL EFFECT OF IL-7-ENHANCED CD19 EXPRESSION ON HUMAN B-CELL PRECURSORS | 1993 |
Dr. Wen-Kai Weng, MDPHD has not yet indicated the hospitals that he is affiliated with.
Accepts New Patients: Yes
Dr. Wen-Kai Weng, MDPHD has not yet listed the medications that he commonly prescribes.
Dr. Wen-Kai Weng, MDPHD has not yet added any information about his practice's billing policies and payment options.
